[HTML][HTML] High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients
EN Suspitsin, NY Sherina, DN Ponomariova… - Hereditary cancer in …, 2009 - Springer
Background A significant portion of ovarian cancer (OC) cases is caused by germ-line
mutations in BRCA1 or BRCA2 genes. BRCA testing is cheap in populations with founder …
mutations in BRCA1 or BRCA2 genes. BRCA testing is cheap in populations with founder …
ATL
TV Gorodnova, KB Kotiv, AO Ivantsov… - International Journal of …, 2018 - ijgc.bmj.com
Objectives Cisplatin and mitomycin C exert high activity towards BRCA1-deficient cells. This
study aimed to evaluate the efficacy of a combination of these drugs in hereditary BRCA1 …
study aimed to evaluate the efficacy of a combination of these drugs in hereditary BRCA1 …
BRCA1-associated and sporadic ovarian carcinomas: outcomes of primary cytoreductive surgery or neoadjuvant chemotherapy
T Gorodnova, A Sokolenko, V Ni, A Ivantsov… - International Journal of …, 2019 - ijgc.bmj.com
Objective Tumors arising in BRCA1/2 mutation carriers are characterized by increased
platinum sensitivity; however, it is unknown whether this feature should be considered while …
platinum sensitivity; however, it is unknown whether this feature should be considered while …
Mitomycin C plus cisplatin for systemic treatment of recurrent BRCA1-associated ovarian cancer
TV Gorodnova, AP Sokolenko, SV Kondratiev… - Investigational New …, 2020 - Springer
Background Previous studies on neoadjuvant therapy for BRCA1-driven ovarian cancer
(OC) demonstrated higher efficacy of mitomycin C plus cisplatin combination as compared to …
(OC) demonstrated higher efficacy of mitomycin C plus cisplatin combination as compared to …
Accumulation of tumor cells with retained heterozygous BRCA1 status during platinum therapy: A probable mechanism of attenuation of tumor response in BRCA1 …
ES Kuligina, TV Gorodnova, AP Sokolenko… - Cancer Research, 2016 - AACR
Abstract Approximately 15-25% ovarian cancer (OC) patients carry germ-line mutation in
BRCA1 or BRCA2 genes. BRCA deficiency underlies the pronounced sensitivity of tumor …
BRCA1 or BRCA2 genes. BRCA deficiency underlies the pronounced sensitivity of tumor …